Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 1,691 | 184 | 1,487 |
| Samples | 459 | 76 | 378 |
| Peptides | 339 | 51 | 299 |
Function
OPCML · Opioid binding protein/cell adhesion molecule like
This gene encodes a member of the IgLON subfamily in the immunoglobulin protein superfamily of proteins. The encoded preprotein is proteolytically processed to generate the mature protein. This protein is localized in the plasma membrane and may have an accessory role in opioid receptor function. This gene has an ortholog in rat and bovine. The opioid binding-cell adhesion molecule encoded by the rat gene binds opioid alkaloids in the presence of acidic lipids, exhibits selectivity for mu ligands and acts as a GPI-anchored protein. Since the encoded protein is highly conserved in species during evolution, it may have a fundamental role in mammalian systems. Alternative splicing results in multiple transcript variants, at least one of which encodes an isoform that is proteolytically processed. [provided by RefSeq, Jan 2016].
Isoforms & Proteins
4 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 288 amino-acid changes on canonical ENST00000524381 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in OPCML · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in OPCML – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Endometrial Carcinoma | 4/42 10% | 17/612 3% |
| Other Solid Cancers | 2/94 2% | 48/1515 3% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 21/810 3% |
| Non-Small Cell Lung Carcinoma | 12/304 4% | 25/1390 2% |
| Melanoma | 6/210 3% | 37/1899 2% |
| Colorectal Carcinoma | 12/143 8% | 57/3239 2% |
| Glioblastoma | 2/98 2% | 0/0 0% |
| Gastric Carcinoma | 2/74 3% | 28/1809 2% |
| Esophageal Carcinoma | 0/23 0% | 12/769 2% |
| Bladder Carcinoma | 4/58 7% | 11/956 1% |
| Ovarian Carcinoma | 8/109 7% | 8/998 1% |
| Neuroendocrine Tumour | 4/154 3% | 6/577 1% |
| Acute Myeloid Leukemia | 1/90 1% | 0/0 0% |
| Cervical Carcinoma | 0/35 0% | 5/422 1% |
| Germ Cell Tumour | 2/25 8% | 0/169 0% |
| Esophageal Squamous Cell Carcinoma | 2/51 4% | 21/2550 1% |
| Head and Neck Carcinoma | 0/85 0% | 12/1574 1% |
| Hepatocellular Carcinoma | 0/46 0% | 15/2210 1% |
| Pancreatic Carcinoma | 1/89 1% | 9/1611 1% |
| Plasma Cell Myeloma | 0/44 0% | 2/305 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 4/752 1% |
| Other Sarcomas | 0/69 0% | 4/699 1% |
| Burkitts Lymphoma | 1/32 3% | 0/196 0% |
| Non-Cancerous | 0/104 0% | 4/830 0% |
| Prostate Carcinoma | 2/13 15% | 7/2105 0% |
| Meningioma | 0/3 0% | 1/252 0% |
| Glioma | 0/52 0% | 8/2127 0% |
| Ewings Sarcoma | 0/63 0% | 1/262 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 5/1592 0% |
| Breast Carcinoma | 3/144 2% | 6/3264 0% |
Mutation Distribution
Where OPCML is mutated · all tissues, split by cell line vs tissue
How many mutations in OPCML were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 53 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 1,691 mutations in OPCML
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|